First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

• Unité de recherche: INNOSUISSE
• Numéro de projet: 121.049 IP-LS
• Titre du projet anglais: First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Mots-clé (Anglais)

Life sciences, Human medicine

Résumé des résultats (Abstract) (Anglais)

Ymmunobio is a biotech firm developing GI cancer therapies targeting the Neuronal Pentraxin Receptor (NPTXR), found in 70-80% of metastatic gastric and colorectal cancers. Their lead product, YB-800, a humanized antibody, is advanced in collaboration with PSI, aiming for clinical proof of concept.